Skip to main content
    S

    Supernus Pharmaceuticals, Inc. (SUPN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $28.83
    -0.89 (-2.99%)

    Market Cap: $1.52B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Supernus Pharmaceuticals, Inc. (SUPN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 3, 2026. Financial statements from company filings, amounts in US dollars.

    Supernus Pharmaceuticals reported revenue of $718.95M for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was -$38.55M with a net margin of -5.4%, operating cash flow was $47.33M and free cash flow was $45.99M. The quarter ended Jun 30, 2026 had revenue of $219.06M and net income of -$58.37M.

    Revenue and Margins

    The operating margin was -8.7% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $425.08M, a compound annual rate of 6.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$718.95M+8.6%89.6%-8.7%-5.4%
    Dec 2024$661.82M+8.9%88.2%12.3%11.2%
    Dec 2023$607.52M-8.9%86.2%-0.9%0.2%
    Dec 2022$667.24M+15.1%86.9%6.9%9.1%
    Dec 2021$579.77M+11.4%87.1%14.8%9.2%
    Dec 2020$520.40M+32.5%89.9%33.4%24.4%
    Dec 2019$392.75M-3.9%95.8%37.8%28.8%
    Dec 2018$408.90M+35.3%96.2%35.3%27.1%
    Dec 2017$302.24M-28.9%95.0%32.9%19.0%
    Dec 2016$425.08MN/A97.2%12.8%21.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$718.95M$661.82M$607.52M$667.24M$579.77M$520.40M$392.75M$408.90M$302.24M$425.08M
    Cost of revenue$74.56M$77.91M$83.78M$87.22M$75.06M$52.46M$16.66M$15.36M$15.21M$11.99M
    Gross profit$644.39M$583.91M$523.74M$580.02M$504.71M$467.94M$376.10M$393.54M$287.02M$413.10M
    Research and development$106.23M$108.80M$91.59M$74.55M$90.47M$75.96M$69.10M$89.21M$49.58M$42.79M
    Operating income-$62.28M$81.67M-$5.27M$46.12M$86.03M$173.70M$148.57M$144.44M$99.54M$54.22M
    Net income-$38.55M$73.86M$1.32M$60.71M$53.42M$126.95M$113.06M$110.99M$57.28M$91.22M
    EBITDA$41.00M$180.11M$90.45M$158.70M$123.69M$200.48M$165.82M$157.42M$108.24M$57.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$219.06M$207.71M$211.57M$192.10M$165.45M$149.82M$174.16M$175.69M$168.32M$143.64M$164.31M$153.88M
    Gross profit$185.39M$184.31M$188.56M$173.14M$148.63M$134.06M$148.06M$158.11M$150.41M$127.33M$144.69M$134.28M
    Operating income-$57.96M-$8.33M-$3.94M-$60.23M$12.14M-$10.26M$21.41M$40.84M$22.57M-$3.15M-$996.00K$8.14M
    Net income-$58.37M-$2.29M-$4.11M-$45.12M$22.50M-$11.83M$15.33M$38.50M$19.92M$124.00K$1.18M-$15.98M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $31.05M by $97.40M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.45B$1.37B$1.28B$1.70B$1.69B$1.50B$1.16B$977.81M$424.46M$309.57M
    Current assets$644.18M$686.07M$493.11M$734.15M$601.59M$630.42M$472.64M$493.49M$228.45M$151.40M
    Cash and equivalents$128.45M$69.33M$75.05M$93.12M$203.43M$288.64M$181.38M$192.25M$100.30M$66.40M
    Total liabilities$390.93M$332.34M$356.16M$816.30M$873.30M$759.24M$564.85M$524.79M$156.98M$117.81M
    Short-term debt$31.05M$47.34M$52.07M$423.09M$44.84M$30.90M$0$2.18M$4.28M$69.38M
    Long-term debtN/AN/AN/AN/A$379.25M$361.75M$345.17M$329.46M$0$4.17M
    Shareholder equity$1.06B$1.04B$921.52M$886.20M$815.85M$744.86M$595.43M$453.02M$267.48M$191.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$1.43B$1.50B$1.45B$1.42B$1.38B$1.35B$1.37B$1.34B$1.32B$1.30B$1.28B$1.29B
    Total liabilities$396.88M$423.92M$390.93M$370.09M$318.50M$316.58M$332.34M$335.55M$358.38M$374.92M$356.16M$372.97M
    Cash and equivalents$179.95M$184.87M$128.45M$151.37M$144.71M$115.85M$69.33M$31.67M$52.09M$63.40M$75.05M$94.98M
    Shareholder equity$1.03B$1.08B$1.06B$1.05B$1.06B$1.03B$1.04B$1.01B$957.45M$929.17M$921.52M$912.19M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 97.2% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$47.33M$171.95M$111.08M$116.83M$127.13M$138.40M$143.13M$128.99M$114.64M$66.81M
    Capital expenditures$1.34M$725.00K$551.00K$412.00K$2.04M$3.69M$1.39M$844.00K$2.03M$1.60M
    Free cash flow$45.99M$171.23M$110.53M$116.41M$125.08M$134.71M$141.74M$128.14M$112.61M$65.21M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$10.44M$0N/A
    Investing cash flow$4.11M-$189.87M$268.73M-$216.66M-$81.91M-$34.70M-$157.92M-$413.48M-$86.42M-$35.96M
    Financing cash flow$9.13M$12.19M-$397.88M-$10.48M-$130.42M$3.56M$3.93M$376.44M$5.68M$2.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$4.81M$66.52M$19.86M-$61.66M$58.53M$30.60M$44.41M$53.52M$35.62M$38.40M$44.96M$35.88M
    Capital expenditures$568.00K$0$427.00K$129.00K$455.00K$327.00K$213.00K$200.00K$64.00K$248.00K$36.00K$150.00K
    Free cash flow-$5.38M$66.52M$19.43M-$61.79M$58.08M$30.27M$44.19M$53.32M$35.56M$38.15M$44.92M$35.73M
    Last 12 quarters

    Frequently Asked Questions About SUPN

    What is Supernus Pharmaceuticals' annual revenue?

    Supernus Pharmaceuticals reported revenue of $718.95M for the fiscal year ended Dec 31, 2025.

    How fast is Supernus Pharmaceuticals' revenue growing?

    Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.5%.

    Is Supernus Pharmaceuticals profitable?

    No. Supernus Pharmaceuticals reported net income of -$38.55M for the fiscal year ended Dec 31, 2025, with a net margin of -5.4%.

    How much free cash flow does SUPN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $47.33M minus capital expenditures of $1.34M produced free cash flow of $45.99M.

    How much debt does Supernus Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $31.05M and cash and equivalents of $128.45M.